- Current report filing (8-K)
August 09 2010 - 3:49PM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported):
August 9, 2010
MARTEK BIOSCIENCES CORPORATION
(Exact name of registrant as specified in its
charter)
Delaware
|
|
0-22354
|
|
52-1399362
|
(State or other jurisdiction of
incorporation or organization)
|
|
(Commission File
Number)
|
|
(I.R.S. Employer
Identification No.)
|
6480 Dobbin Road, Columbia Maryland
|
|
21045
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone
number, including area code:
(410) 740-0081
(Former name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o
Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant
to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
INFORMATION TO BE INCLUDED IN THE
REPORT
Item 7.01 Regulation FD Disclosure.
Attached
hereto as Exhibit 99.1 and incorporated herein by reference are slides to
be used in connection with the presentation by Martek Biosciences
Corporation at the 30th Annual Canaccord Genuity Growth Conference in
Boston, MA. The company will be presenting on Wednesday, August 11th at
11:30 a.m. Eastern Time.
Item 9.01. Financial Statements and Exhibits.
(d)
Exhibits
Exhibit No.
|
|
|
99.1
|
|
Martek
Biosciences Corporation Presentation
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Martek
Biosciences Corporation
|
|
|
|
Date:
August 9, 2010
|
By:
|
/s/
Peter L. Buzy
|
|
|
Peter L. Buzy
|
|
|
Chief
Financial Officer, Treasurer and Executive Vice President for Finance and
Administration
|
3
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Martek (NASDAQ:MATK)
Historical Stock Chart
From Jul 2023 to Jul 2024